CL2015002897A1 - Inhibidores de bace1 - Google Patents

Inhibidores de bace1

Info

Publication number
CL2015002897A1
CL2015002897A1 CL2015002897A CL2015002897A CL2015002897A1 CL 2015002897 A1 CL2015002897 A1 CL 2015002897A1 CL 2015002897 A CL2015002897 A CL 2015002897A CL 2015002897 A CL2015002897 A CL 2015002897A CL 2015002897 A1 CL2015002897 A1 CL 2015002897A1
Authority
CL
Chile
Prior art keywords
bace1 inhibitors
bace1
inhibitors
oxazin
alzheimer
Prior art date
Application number
CL2015002897A
Other languages
English (en)
Inventor
Hans Hilpert
Thomas Woltering
Roland Humm
Thorsten Muser
Christian Schnider
Roger Wermuth
Original Assignee
Siena Biotech Spa
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48050604&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002897(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Siena Biotech Spa, Hoffmann La Roche filed Critical Siena Biotech Spa
Publication of CL2015002897A1 publication Critical patent/CL2015002897A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

COMPUESTOS DERIVADOS DE 1,3-OXAZIN-4-IL-PIRIDINA; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA Y EL USO EN EL TRATAMIENTO DEL ALZHEIMER.
CL2015002897A 2013-04-11 2015-09-29 Inhibidores de bace1 CL2015002897A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13163430 2013-04-11

Publications (1)

Publication Number Publication Date
CL2015002897A1 true CL2015002897A1 (es) 2016-06-03

Family

ID=48050604

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002897A CL2015002897A1 (es) 2013-04-11 2015-09-29 Inhibidores de bace1

Country Status (20)

Country Link
US (1) US11447478B2 (es)
EP (1) EP2984086A1 (es)
JP (2) JP6574756B2 (es)
KR (1) KR102247765B1 (es)
CN (1) CN105431430B (es)
AU (1) AU2014253275B2 (es)
BR (1) BR112015019412A8 (es)
CA (1) CA2900433C (es)
CL (1) CL2015002897A1 (es)
EA (1) EA027860B1 (es)
HK (1) HK1216533A1 (es)
IL (2) IL240263A0 (es)
MA (2) MA38556A1 (es)
MX (1) MX2015014083A (es)
MY (1) MY174747A (es)
PE (1) PE20151748A1 (es)
PH (1) PH12015502365A1 (es)
SG (1) SG11201508412XA (es)
UA (1) UA119141C2 (es)
WO (1) WO2014166906A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
EP2511268B2 (en) † 2009-12-11 2021-02-17 Shionogi & Co., Ltd. Oxazine derivative
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
JP6389830B2 (ja) 2013-03-01 2018-09-12 アムジエン・インコーポレーテツド ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法
US9085576B2 (en) 2013-03-08 2015-07-21 Amgen Inc. Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
WO2016022724A1 (en) 2014-08-08 2016-02-11 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
WO2017061534A1 (en) 2015-10-08 2017-04-13 Shionogi & Co., Ltd. Dihydrothiazine derivatives
JP2017071603A (ja) * 2015-10-09 2017-04-13 塩野義製薬株式会社 ジヒドロチアジンまたはジヒドロオキサジン誘導体を含有する医薬組成物
EP3423450B1 (en) 2016-03-01 2019-11-27 H. Hoffnabb-La Roche Ag Bace 1 inhibitors
JP7353708B2 (ja) 2018-04-27 2023-10-02 塩野義製薬株式会社 選択的ｂａｃｅ１阻害活性を有するテトラヒドロピラノオキサジン誘導体
KR102467525B1 (ko) 2020-11-26 2022-11-14 이대근 작업자 중개 장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
WO2008141239A1 (en) 2007-05-10 2008-11-20 Acadia Pharmaceuticals Inc. Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors
CN101910143B (zh) 2008-01-18 2013-08-21 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
EP2511268B2 (en) * 2009-12-11 2021-02-17 Shionogi & Co., Ltd. Oxazine derivative
EP2663561B1 (en) 2011-01-13 2016-03-16 Novartis AG Novel heterocyclic derivatives and their use in the treatment of neurological disorders
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
WO2012147763A1 (ja) * 2011-04-26 2012-11-01 塩野義製薬株式会社 オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
MX2013014007A (es) * 2011-06-07 2014-03-12 Hoffmann La Roche [1,3] oxazinas.
BR112013031098A2 (pt) * 2011-06-07 2016-12-06 Hoffmann La Roche halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
AR089781A1 (es) 2012-01-26 2014-09-17 Hoffmann La Roche Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
JP6389830B2 (ja) * 2013-03-01 2018-09-12 アムジエン・インコーポレーテツド ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法

Also Published As

Publication number Publication date
US11447478B2 (en) 2022-09-20
MA44948A1 (fr) 2020-06-30
UA119141C2 (uk) 2019-05-10
PH12015502365B1 (en) 2016-02-22
NZ710050A (en) 2021-03-26
CA2900433A1 (en) 2014-10-16
IL265496A (en) 2019-05-30
HK1216533A1 (zh) 2016-11-18
BR112015019412A8 (pt) 2019-11-12
BR112015019412A2 (pt) 2017-07-18
JP2016515638A (ja) 2016-05-30
JP6574756B2 (ja) 2019-09-11
EP2984086A1 (en) 2016-02-17
JP6681451B2 (ja) 2020-04-15
PE20151748A1 (es) 2015-12-02
US20160052920A1 (en) 2016-02-25
MA38556A1 (fr) 2017-09-29
KR102247765B1 (ko) 2021-05-06
CN105431430B (zh) 2019-05-28
CN105431430A (zh) 2016-03-23
WO2014166906A1 (en) 2014-10-16
AU2014253275B2 (en) 2018-10-18
KR20150142001A (ko) 2015-12-21
JP2019031532A (ja) 2019-02-28
EA201591541A1 (ru) 2016-02-29
MY174747A (en) 2020-05-13
EA027860B1 (ru) 2017-09-29
SG11201508412XA (en) 2015-11-27
CA2900433C (en) 2021-06-22
MX2015014083A (es) 2016-07-26
AU2014253275A1 (en) 2015-07-16
IL240263A0 (en) 2015-09-24
PH12015502365A1 (en) 2016-02-22

Similar Documents

Publication Publication Date Title
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015002897A1 (es) Inhibidores de bace1
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína